Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Date:

November 14, 2024

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.

Source link

Will Rivian be Volkswagen’s software savior? VW is betting $5.8B it will

Tropical Storm Sara forms in Caribbean, could threaten Florida next week

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Recent posts

Betting markets now see Kamala Harris beating Donald Trump in November

What the presidential election means for gold, oil, natural gas and other commodities

Cigna’s PBM Express Scripts sues the FTC, seeking retraction of drug-cost report

Trump and Harris spar over fracking amid America’s soaring energy needs

Applebee’s parent’s stock slides 5% after Truist downgrades on worry about slowing sales

October jobs report was a ‘head fake.’ Look at these numbers instead before Election Day.

Trump trades take off as voting results tilt in former president’s favor

B. Riley Financial’s stock drops 30% after it suspends dividend and projects a loss

Walgreens Boots Alliance’s stock slides after profit miss and lowered guidance

Amazon Prime Video’s ad event beat targets. That’s good news for the stock, says BofA.

D.R. Horton’s stock soars as affordable homes are still in short supply

Hopes for cooling inflation are stifled by Wall Street’s expectations for Trump 2.0

Intuit stock rises on upbeat full-year forecast amid a pivot toward AI

Chipotle’s stock rallies as renewed focus on quicker service helps second-quarter results

Prescription-drug middlemen face mounting bipartisan criticism on Capitol Hill

Related articles

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Powell says Fed doesn’t need to hurry to cut interest rates

Off-price retailers could thrive, BofA says, citing this bullish data point

Republicans clinch control of House, setting stage for quicker action on extending tax cuts

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Cava is riding a strong wave, but the stock’s quadrupling in 2024 has analysts wary

Wells Fargo touches all-time high as analyst hikes price target to new level

Tesla is likely to thrive in a Trump administration. These are the ways these analysts see it happening.

Company

Follow us